Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2003

View Archived Issues

New tricyclic macrolide antibiotics identified at Abbott

Merck describes new selective androgen receptor modulators for osteoporosis therapy

Another series of chemokine CCR2 modulators newly identified at Merck

Novel anti-herpes virus agents prepared and tested by GSK team

Genelabs patent covers new NS5B inhibitors for HCV infection

Pivotal stage of AI-700 phase III program commences

Kinexium to manage development of new departments at Generex

Phase I trial tests FG-3019 in IPF patients

Second approvable letter for Symlin

Naropin recommended for E.U. approval for new indication

Second phase II trial for Corus-1030

CTCE-9908 enters phase I testing

Enrollment goal reached for phase III Xibrom trial

Orphan drug designation for Photopoint MV-2101

BAMF Technology to be transitioned to Eclipse Diagnostics

Oxford BioMedica oncology pipeline update

deCODE achieves milestones in Roche DNA-based diagnostics alliance

MLN-2222 enters phase I

Clinical effects of PKC-412 in acute myeloid leukemia

Antitumor activity of thalidomide analogues in hematological malignancies

Cardioprotection against ischemia/reperfusion injury via PPARalpha activation shown in mice

Septic diaphragm dysfunction attenuated with geranylgernaylacetone induction of HSD70 in rats

NDA for lower dose Yasmin accepted for filing

XTL Biopharmaceuticals reviews recent developments

GW-4064, a FXR agonist, provides hepatoprotection in rat models of cholestasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 11, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...